Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA: WUXI APPTEC (02359.HK) Top Picks in CN Pharma CRO/ CDMO Sectors, Expected to Outperform Peers This Yr
Recommend 6 Positive 11 Negative 4 |
||||
|
||||
|
WUXI APPTEC (02359.HK) issued a positive profit alert forecasting a 9% revenue growth in 4Q25, with a 36% YoY growth in non-IFRS revenue, beating market consensus by 2% and 3% each, CLSA released a research report saying. The broker believed that the better-than-expected results is mainly due to the Company's strong integrated 'contract research, development and manufacturing organization (CRDMO model)', robust growth in TIDES business, and China's competitiveness in the global small molecule supply chain. Looking ahead to 2026, CLSA believed that, for China's healthcare sector, profit delivery will be more important than valuation expansion, and WUXI APPTEC is expected to outperform its peers. The broker listed WUXI APPTEC as its top pick in China's CRO/ CDMO industries. Therefore, CLSA kept rating at Outperform for WUXI APPTEC and a target price of $143.4. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
